RNA interference for the treatment of papillomavirus disease.
Human Papillomavirus (HPV)-induced diseases are a significant burden on our healthcare system and current therapies are not curative. Vaccination provides significant prophylactic protection but effective therapeutic treatments will still be required. RNA interference (RNAi) has great promise in providing highly specific therapies for all HPV diseases yet this promise has not been realised. Here we review the research into RNAi therapy for HPV in vitro and in vivo and examine the various targets and outcomes. We discuss the idea of using RNAi with current treatments and address delivery of RNAi, the major issue holding back clinical adoption. Finally, we present our view of a potential path to the clinic.
The University of Queensland Diamantina Institute, Brisbane, Australia.
Richa
R
Singhania
Norliana
N
Khairuddin
Daniel
D
Clarke
Nigel Aj
NA
McMillan
Clinical trial; RNA interference; delivery; human papillomavirus; shRNA.; siRNA